Once-monthly oral PrEP moves into late-stage trials

Back to the "HIV and Co-Infections News" list

An investigational once-monthly pill holds promise for HIV pre-exposure prophylaxis (PrEP), according to mid-stage study results presented at the 13th International AIDS Society Conference on HIV Science (IAS 2025). With favourable pharmacokinetics and a good safety profile, Merck said MK-8527 will soon move into phase III trials.

Much of the enthusiasm at the conference focused on the recent US approval of twice-yearly lenacapavir PrEP (Yeztugo), but oral medications may be easier to roll out worldwide than injections administered by a healthcare provider in a clinic.

In addition, long-acting injectables aren’t for everyone: some people dislike needles or prefer the simplicity of taking a pill. In a survey of men who have sex with men in the US, respondents indicated that oral monthly PrEP was the preferred modality compared with what’s currently available.

Read the full news story at aidsmap.


All aidsmap reports from IAS 2025 can be accessed here.


SEE ALSO:

All HIV i-Base reports from IAS 2025 can be accessed here.


 

Source : aidsmap

Get involved

Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?

Subscribe

Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.